Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Verinurad and Allopurinol Formulations
NCT04550234Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of verinurad in hyperuricemia and chronic kidney disease (CKD) (5 arms), sponsored by AstraZeneca. Primary endpoints: Area Under Plasma Concentration-time Curve From 0 to Infinity at Day 4, Area Under Plasma Concentration-time Curve From Zero to the Last Quantifiable Concentration at Day 4 and 1 more. Started Apr 2021; status: completed.
02
Drugs
verinurad
03
Conditions
hyperuricemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04550234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04550234.